Lysophospholipids and cancer: current status and perspectives

被引:9
|
作者
Raynal, P [1 ]
Montagner, A [1 ]
Dance, M [1 ]
Yart, A [1 ]
机构
[1] Hop Purpan, Ctr Physiopathol Toulouse Purpan, INSERM,LML, U563,IFR 30,Dept Lipoprot & Mediateurs Lipidiques, F-31059 Toulouse, France
来源
PATHOLOGIE BIOLOGIE | 2005年 / 53卷 / 01期
关键词
lysophosphatidic acid; cancer; oncolipid; growth factor; autotaxin; sphingosine; 1-phosphate;
D O I
10.1016/j.patbio.2004.01.005
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Circulating phospholipids carrying a single esterified fatty acid, the so-called lysophospholipids, are no,,v considered as mediators of the intercellular communication. Their major members are the lysophosphatidic acid and the sphingosine I-phosphate. two molecules displaying biological activities similar to those of growth factors or cytokines, through a recently identified subfamily of G protein-coupled receptors. They are involved in various biological processes, e.g., brain development and angiogenesis. but the following evidences suggest that these. lipids are also significant actors of tumour development: (i) they stimulate the growth, survival and migration of tumour cells from various origins (ovary, prostate, glioblastoma...); (ii) they are abundant in malignant effusions; (iii) the lysophospholipid-producing enzymes are tumourigenic. Even if it remains necessary to define the role of these "oncolipids" in relationship with oncogenes and tumor suppression, they may well be the mediators of an efficient autostimulatory system of the proliferating and migratory capacities of cancer cells, suggesting that lysophospholipids could represent novel valuable targets for anticancer pharmacology. (C) 2004 Elsevier SAS. Tous droits reserves.
引用
收藏
页码:57 / 62
页数:6
相关论文
共 50 条
  • [1] Cancer nanotechnology: current status and perspectives
    Kemp, Jessica A.
    Kwon, Young Jik
    NANO CONVERGENCE, 2021, 8 (01)
  • [2] Current status and perspectives in cancer chemotherapy
    Ogawa M.
    Breast Cancer, 1999, 6 (4) : 270 - 274
  • [3] Cancer nanotechnology: current status and perspectives
    Jessica A. Kemp
    Young Jik Kwon
    Nano Convergence, 8
  • [4] Current status and perspectives of brachytherapy for breast cancer
    Csaba Polgár
    Tibor Major
    International Journal of Clinical Oncology, 2009, 14
  • [5] Current status and perspectives of hyperthermia in cancer therapy
    Hiraoka, M
    Nagata, Y
    Mitsumori, M
    Sakamoto, M
    Masunaga, S
    PORTABLE SYNCHROTRON LIGHT SOURCES AND ADVANCED APPLICATIONS, 2004, 716 : 102 - 105
  • [6] Breast Cancer: Current Perspectives on the Disease Status
    Ullah, Mohammad Fahad
    BREAST CANCER METASTASIS AND DRUG RESISTANCE: CHALLENGES AND PROGRESS, 2ND EDITION, 2019, 1152 : 51 - 64
  • [7] Current status and perspectives of brachytherapy for prostate cancer
    Yoshioka, Yasuo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (01) : 31 - 36
  • [8] Current status and perspectives of brachytherapy for prostate cancer
    Yasuo Yoshioka
    International Journal of Clinical Oncology, 2009, 14
  • [9] Current status and perspectives of brachytherapy for breast cancer
    Polgar, Csaba
    Major, Tibor
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (01) : 7 - 24
  • [10] Current status and perspectives of brachytherapy for cervical cancer
    Takafumi Toita
    International Journal of Clinical Oncology, 2009, 14